<div id="readability-page-1"><p>Douglas Lane &amp; Associates LLC lowered its stake in shares of  Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 1.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,444,268 shares of the company's stock after selling 68,407 shares during the period. Douglas Lane &amp; Associates LLC owned 0.69% of Elanco Animal Health worth $69,368,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p><div><p><span></span><span>Get <strong>Elanco Animal Health</strong> alerts:</span></p></div><ul><li>Bullish or Bearish? Vetting Animal Health Care Stocks</li></ul><p>Other hedge funds and other institutional investors have also recently modified their holdings of the company. First Horizon Advisors Inc. increased its holdings in  Elanco Animal Health by 184.3% in the 2nd quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company's stock valued at $53,000 after acquiring an additional 2,414 shares during the last quarter.  Caitong International Asset Management Co. Ltd grew its position in shares of  Elanco Animal Health by 261.6% during the second quarter. Caitong International Asset Management Co. Ltd now owns 4,039 shares of the company's stock valued at $58,000 after purchasing an additional 2,922 shares in the last quarter.  Geneos Wealth Management Inc. increased its holdings in shares of  Elanco Animal Health by 53.7% in the second quarter. Geneos Wealth Management Inc. now owns 5,954 shares of the company's stock worth $85,000 after purchasing an additional 2,080 shares during the last quarter.  EverSource Wealth Advisors LLC increased its holdings in shares of  Elanco Animal Health by 26.4% in the second quarter. EverSource Wealth Advisors LLC now owns 6,379 shares of the company's stock worth $91,000 after purchasing an additional 1,332 shares during the last quarter.  Finally, Parallel Advisors LLC lifted its position in shares of  Elanco Animal Health by 66.6% in the second quarter. Parallel Advisors LLC now owns 6,432 shares of the company's stock worth $92,000 after buying an additional 2,572 shares in the last quarter. Institutional investors own  97.48% of the company's stock. </p><h2>Wall Street Analyst Weigh In</h2><p>A number of analysts have issued reports on the company. Barclays began coverage on Elanco Animal Health in a research note on Tuesday, December 9th. They issued an &#34;overweight&#34; rating and a $30.00 price objective on the stock. Morgan Stanley boosted their price target on shares of Elanco Animal Health from $18.00 to $22.00 and gave the stock an &#34;equal weight&#34; rating in a research report on Thursday. Zacks Research lowered shares of Elanco Animal Health from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Thursday, November 6th. UBS Group lifted their price objective on shares of Elanco Animal Health from $25.00 to $27.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, November 6th. Finally, Argus upgraded shares of Elanco Animal Health from a &#34;hold&#34; rating to a &#34;buy&#34; rating and set a $25.00 target price on the stock in a research report on Wednesday, November 19th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued  a Buy rating, three have given a Hold rating and one  has issued  a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $23.78.</p><ul><li>Zoetis Declares New Dividend, Hinting At Undervaluation</li></ul><p><b>Read Our Latest Research Report on Elanco Animal Health</b></p><h2>Elanco Animal Health Stock Performance</h2><p>Elanco Animal Health stock opened at $22.28 on Friday. Elanco Animal Health Incorporated has a 1-year low of $8.02 and a 1-year high of $23.70. The company's 50-day moving average is $21.92 and its 200 day moving average is $18.37. The firm has a market capitalization of $11.07 billion, a P/E ratio of 371.40, a price-to-earnings-growth ratio of 3.41 and a beta of 1.86. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.40 and a quick ratio of 1.23. </p><ul><li>2 Contrarian Stock Picks With Major Upside</li></ul><p>Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.06. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The firm had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same period in the prior year, the business posted $0.13 earnings per share. The company's revenue for the quarter was up 10.4% on a year-over-year basis. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS.  Research analysts forecast that  Elanco Animal Health Incorporated will post 0.91 EPS for the current year. </p><h2>Insider Activity at Elanco Animal Health</h2><p>In other Elanco Animal Health news, Director Lawrence Erik Kurzius acquired 10,000 shares of the company's stock in a transaction dated Friday, December 12th. The shares were purchased at an average cost of $21.30 per share, for a total transaction of $213,000.00. Following the completion of the purchase, the director owned 131,773 shares in the company, valued at approximately $2,806,764.90. This trade represents a 8.21% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Rajeev A. Modi acquired 4,500 shares of the business's stock in a transaction that occurred on Thursday, December 11th. The shares were acquired at an average cost of $21.33 per share, for a total transaction of $95,985.00. Following the completion of the acquisition, the insider owned 123,082 shares of the company's stock, valued at $2,625,339.06. This trade represents a 3.79% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 43,450 shares of company stock valued at $937,883 over the last ninety days. Company insiders own  0.89% of the company's stock. </p><h2>Elanco Animal Health Company Profile</h2> (Free Report)<p>Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.  </p><p>Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Elanco Animal Health</li><li>How Technical Indicators Can Help You Find Oversold Stocks </li><li>These 3 Banks Are Rallying Into Year-End, But Will It Continue?</li><li>What is a Death Cross in Stocks?</li><li>3 Surging Stocks Just Got the Ultimate Stamp of Approval From the S&amp;P 500</li><li>3 REITs to Buy and Hold for the Long Term</li><li>This ETF Caught a Major Tailwind After the Fed’s Rate Cut</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVMQU4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVMQU4"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Elanco Animal Health Right Now?</h2><p>Before you consider Elanco Animal Health, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elanco Animal Health wasn't on the list.</p><p>While Elanco Animal Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ELAN

<p>Douglas Lane & Associates LLC reduced its stake in Elanco Animal Health by 1.9% in Q3, owning 3,444,268 shares worth $69.37 million. Other investors increased their holdings. Analysts have mixed ratings, with an average target price of $23.78. Elanco's stock opened at $22.28, with a market cap of $11.07 billion. Recent earnings exceeded expectations, reporting $0.19 EPS and $1.14 billion revenue.</p>

Douglas Lane & Associates LLC Cuts Stake in Elanco Animal Health Incorporated $ELAN